Introduction {#Sec1}
============

Adult-onset autoimmune diabetes, associated with diabetes-associated autoantibodies, often presents a similar clinical phenotype to type 2 diabetes mellitus \[[@CR1]--[@CR3]\]. In patients with this clinical phenotype, known as latent autoimmune diabetes of adults (LADA), β cell function decreases about threefold faster than in type 2 diabetes \[[@CR4]\]. As a result, treatment needs to be implemented early and aggressively, yet even on insulin therapy such patients can show worse diabetes control \[[@CR5]--[@CR7]\]. Early therapeutic intervention requires early diagnosis. For LADA, the diagnostic criteria are controversial \[[@CR8]\], but the widely accepted criteria from the Immunology of Diabetes Society (IDS) are: (1) adult-onset (\>30 years), (2) insulin independency at diagnosis, and (3) positive islet autoantibodies \[[@CR2], [@CR9]\].

Although the genetic background contributed a lot to the onset of autoimmune diabetes, islet autoantibodies are the most widely used in practice for the diagnosis \[[@CR10]\]. Of the most widely studied diabetes-associated autoantibodies in LADA, islet cell antibody (ICA) \[[@CR11]\] and glutamic acid decarboxylase antibody (GADA) are the most prevalent in Europeans \[[@CR12], [@CR13]\], though a proportion (about 6 %) only have protein tyrosine phosphatase-2 antibody (IA-2A), insulin autoantibody (IAA) \[[@CR14], [@CR15]\], or zinc transporter 8 autoantibody (ZnT8A) \[[@CR16]--[@CR18]\]. We found that adult-onset autoimmune diabetes is prevalent in China when testing for GADA \[[@CR1]\], while ZnT8A augments the detection of LADA in such Chinese patients \[[@CR17]\]. We have noted differences in the relative frequency of diabetes-associated autoantibodies in European and Chinese childhood-onset type 1 diabetes mellitus patients \[[@CR19]\]. To determine the most appropriate islet autoantibody assaying strategy to identify Chinese patients with LADA from adult-onset non-insulin requiring diabetes patients, we assayed a large cohort for four different diabetes-associated autoantibodies.

Research design and methods {#Sec2}
===========================

LADA China is the first multicenter study to investigate adult-onset autoimmune diabetes in recently diagnosed phenotypic type 2 diabetes mellitus subjects in China in terms of the epidemiology, clinical features, and immunogenetic characteristics \[[@CR1]\]. From this patient cohort (*n* = 4880), we assayed 2388 non-insulin-requiring recently diagnosed diabetes patients with sufficient serum. The inclusion criteria included: (a) 1999 WHO diabetes diagnostic criteria; (b) disease-onset not less than 30 years old; (c) ascertained within 1 year from diagnosis; (d) without ketoacidosis within 6 months after diagnosis; (e) not on insulin therapy after diagnosis. The exclusion criteria included: (a) not with secondary diabetes; (b) women not in pregnancy; (c) not with tumor; (d) not with severe heart, renal, or liver dysfunction. Demographics are shown in Table [1](#Tab1){ref-type="table"}; clinical and laboratory data including age, gender, height, weight, waist circumferences, hip circumferences, HbA1c, cholesterol (CHOL),triglyceride (TG), LDL-chol, HDL-chol, and fasting C-peptide (FCP) were collected locally with standardized methods by trained physicians and clinical biochemistry laboratories.Table 1Clinical characteristics of antibody positive LADA and antibody negative type 2 diabetes mellitus subjectsAb (−) type 2 diabetes mellitusAb (+) LADA*n*2182206Gender (M/F)1250/932129/77Age (years)51.2 ± 11.050.8 ± 11.6BMI (kg/m^2^)25.1 ± 3.824.6 ± 3.5WHR0.91 ± 0.070.91 ± 0.07TG (mmol/L)1.82 (0.39--34.13)1.68 (0.50--14.99)^a^CHOL (mmol/L)5.05 ± 1.195.18 ± 1.18HDL-C (mmol/L)1. 27 ± 0.551.39 ± 0.74LDL-C (mmol/L)2.89 ± 0.942.89 ± 0.97SBP (mmHg)127.6 ± 18.1125.6 ± 18.4DBP (mmHg)81.0 ± 18.580.2 ± 11.1HbA1c (%)8.77 ± 2.879.00 ± 2.52Converted mean HbA1c (mmol/mol)7275FCP (pmol/L)657.3 (5.4--3210.4)573.7 (59.44--1949.59)^a^Compared with Ab (−) group. *P* \< 0.05

All study subjects will centrally assayed for GADA, IA-2A, ZnT8A, and IAA using standardized assays in a core laboratory (Diabetes Center, Central South University). The GADA, IA-2A, and ZnT8A were measured by radioligand assay (RLA), and IAA was by microtiter plate radioimmunoassay (RIA). In the Diabetes Autoantibody Standardized Programme (DASP) 2009, all our assays showed high sensitivity and specificity, i.e., GADA assay (sensitivity 72 %, specificity 98 %), IA-2A assay (sensitivity 66 %, specificity 99 %), ZnT8A assay (sensitivity 66 %, specificity 100 %), and IAA assay (sensitivity 42 %, specificity 98 %), respectively.

Statistics {#Sec3}
==========

All analyses were performed by SPSS 13.0 software. Results were shown as mean ± SD or as median (range) or otherwise documented as positive cases, constituent ratio or ratio. The unpaired *t* tests and analysis of variance for multiple comparisons were used for normally distributed data, and nonparametric tests were used for non-normally distributed data. The difference between classified variables was tested using Chi-squared test or Fisher's exact test if the expected number of subjects in any cell was less than 5. *P* values less than 0.05 were considered significant.

Results {#Sec4}
=======

Frequency of four islet autoantibodies in non-insulin requiring adult-onset diabetes {#Sec5}
------------------------------------------------------------------------------------

Overall, in non-insulin requiring diabetes patients: positivity of GADA, IA-2A, ZnT8A and IAA were 5.8, 1.5, 1.8, and 1.3 % respectively. We stratified all these patients by age, i.e., 30--39, 40--49, 50--59 and over 60 years; the four islet autoantibodies did not show any statistical differences between these age subgroups. However, in every age subgroup, positivity for GADA is higher than for the other three autoantibodies (*P* = or \< 0.01 for each) (Table [2](#Tab2){ref-type="table"}).Table 2Age stratification of the non-insulin-requiring diabetes patients with the positivity for GADA, IA-2A, ZnT8A, and IAAAge (years)CasesGADAIA-2AZnT8AIAA30--393736.17 % (23/373)1.34 % (5/373)^a^2.14 % (8/373)^a^1.07 % (4/373)^b^40--497185.85 % (42/718)2.09 % (15/718)^b^2.51 % (18/718)^a^1.11 % (8/718)^b^50--597535.58 % (42/753)1.06 % (8/753)^b^1.33 % (10/753)^b^1.60 % (12/753)^b^≥605445.70 % (31/544)1.47 % (8/544)^b^1.47 % (8/544)^b^1.10 % (6/544)^b^In total23885.78 % (138/2388)1.51 % (36/2388)^b^1.84 % (44/2388)^b^1.26 % (30/2388)^b^Data were showed as percentage (positive cases/total cases), compared with the GADA positivity. ^a^ *P* \< 0.01, ^b^ *P* \< 0.001

Association of four islet autoantibodies in recently diagnosed adult-onset non-insulin-requiring diabetes {#Sec6}
---------------------------------------------------------------------------------------------------------

Of 2388 patients studied, 206 cases (8.6 %) had islet autoantibodies, of which the majority (177/206; 85.9 %) had a single positive autoantibody, more than had two autoantibodies (17/206; 8.3 %), in turn, more than had three autoantibodies (11/206; 5.3 %). Only one case had all four islet autoantibodies. Overlap of positive autoantibodies is shown in Fig. [1](#Fig1){ref-type="fig"}. Of note the majority of autoantibody positive cases had GADA (138/206, 67 %) (Fig. [2](#Fig2){ref-type="fig"}). Of 206 patients with autoantibodies, a combination assay with GADA plus one other autoantibody could identify 80.1 % (with IAA), 79.6 % (with ZnT8A), and 77.7 % (with IA2A), respectively (Fig. [2](#Fig2){ref-type="fig"}).The hierarchy of likelihood for detecting autoimmune diabetes by autoantibody testing in this cohort was GADA \> IAA \> ZnT8A \> IA2A. When assaying this cohort with three islet autoantibodies, the most effective strategy was the combination of GADA, ZnT8A, and IAA, which could identify about 92.2 % (190/206) of autoimmune diabetes patients of the total of 8.6 % with autoantibodies (Fig. [2](#Fig2){ref-type="fig"}). We have investigated the positivity of IAA, ZnT8A, and IA2A among high and low GADA titer subgroups, and there was no statistical differences for the presence of these autoantibodies in the different GADA titer groups (data not shown).Fig. 1Venn diagram of GADA, IA-2A, ZnT8A, and IAA positivity in adult non-insulin requiring autoimmune diabetes patientsFig. 2Histogram of different assay strategy for GADA, ZnT8A, IA-2A, and IAA in adult-onset autoimmune diabetes. *x* axis stands for different diabetes-associated islet autoantibodies combination strategies. *y* axis stands for the percentage of patients with different assay strategies in a total of 206 adult autoimmune diabetes

Clinical features of subjects with autoantibodies {#Sec7}
-------------------------------------------------

Compared with type 2 diabetes mellitus patients, clinical and laboratory characteristics of adult-onset autoimmune patients were similar, apart from having lower triglycerides (Table [1](#Tab1){ref-type="table"}). Patients with GADA had lower β cell function as estimated by fasting C-peptide (FCP) \[controls vs. GADA (+): 657.3 (5.4--3210.4) vs. 519.3 (105.9--1648.0) pmol/L, *P* \< 0.001\], higher HDL-ch \[controls vs. GADA (+):1.27 ± 0.55 vs. 1.42 ± 0.82 mmol/L, *P* \< 0.05\], and lower SBP \[controls vs. GADA (+): 127.6 ± 18.1 vs. 123.0 ± 17.2 mmHg, *P* \< 0.05\] (Table [3](#Tab3){ref-type="table"}). Though the numbers were small, patients with adult autoimmune diabetes with single autoantibodies, when compared with type 2 diabetes mellitus patients, had significantly lower BMI (with IA2A alone), lower triglycerides (with IA2A or IAA alone), higher HDL (with IA2A alone), higher CHOL (with ZnT8A alone), and higher WHR (with ZnT8A alone)(*P* \< 0.05 for each) (Table [3](#Tab3){ref-type="table"}). Compared with GADA (+) autoimmune diabetes subjects, patients with ZnT8A had higher WHR and SBP (*P* \< 0.05 for each) (Table [3](#Tab3){ref-type="table"}).Table 3Clinical characteristics of GADA, IA-2A, ZnT8A, and IAA positive and autoantibody negative non-insulin required type 2 diabetes mellitus subjectsAbs (−)GADA (+)IA-2A (+) GADA (−)ZnT8A (+) GADA (−)IAA (+) GADA (−)*n*2182138222726Gender (M/F)1250/93284/5412/1018/919/7Age (years)51.2 ± 11.050.48 ± 11.652.1 ± 12.349.56 ± 10.0653.6 ± 12.7BMI (kg/m^2^)25.1 ± 3.824.7 ± 3.823.6 ± 2.5^b^24.8 ± 3.124.6 ± 2.7WHR0.91 ± 0.070.90 ± 0.070.92 ± 0.060.94 ± 0.04ae0.90 ± 0.06TG (mmol/L)1.82 (0.39--34.13)1.70 (0.50--14.99)1.54 (0.67--2.49)^cd^1.73 (0.88--13.36)1.64 (0.64--4.74)^a^CHOL (mmol/L)5.05 ± 1.195.19 ± 1.225.17 ± 1.075.56 ± 1.13^a^4.87 ± 1.07HDL-C (mmol/L)1.27 ± 0.551.42 ± 0.82^a^1.50 ± 0.42^a^1.37 ± 0.681.28 ± 0.45LDL-C (mmol/L)2.89 ± 0.942.84 ± 1.012.99 ± 0.723.25 ± 1.022.82 ± 0.76SBP (mmHg)127.6 ± 18.1123.0 ± 17.2^a^124.0 ± 14.9133.7 ± 23.4e131.9 ± 16.3DBP (mmHg)81.0 ± 18.579.55 ± 11.080.3 ± 8.783.6 ± 13.080.2 ± 10.5HbA1c (%)8.77 ± 2.879.04 ± 2.3910.18 ± 2.519.20 ± 2.167.48 ± 3.09Converted Mean HbA1c (mmol/mol)7275887758FCP (pmol/L)657.3 (5.4--3210.4)519.3 (105.9--1648.0)^b^685.2 (427.0--897.0)887.1 (197.0--1949.6)626.0 (59.44--1774.16)Compared with Abs (−) group. ^a^ *P* \< 0.05, ^b^ *P* \< 0.01, ^c^ *P* \< 0.001; compared with GADA (+) group, ^d^ *P* \< 0.05, ^e^ *P* \< 0.01

Conclusions {#Sec8}
===========

Our previous studies in childhood-onset type 1 diabetes mellitus suggested that the pattern of islet autoantibodies in Chinese patients is different from European patients \[[@CR18]\]. In European childhood-onset type 1 diabetes mellitus subjects, diabetes-associated autoantibodies are prevalent, e.g., GADA (79 %), IA-2A (69 %), ZnT8A (64 %), and IAA (70 %) \[[@CR20]\]. In contrast, in Chinese patients the same autoantibodies are less prevalent: GADA (53 %), IA-2A (26 %), ZnT8A (24 %), and IAA (22 %) \[[@CR18]\]. In both populations, GADA was the most prevalent autoantibody. However, it is well established that the pattern of autoantibodies differs in European adult-onset, compared with childhood-onset, autoimmune diabetes \[[@CR18]\]. In particular, IAA is prevalent in children but far less prevalent in adults, while GADA is by far the most prevalent autoantibody in adult-onset autoimmune diabetes \[[@CR1], [@CR21], [@CR22]\]. Since such autoimmune diabetes patients are easily misdiagnosed as having type 2 diabetes mellitus, it is important to determine the optimum screening strategy for them. This present report is the first to describe the pattern of multiple diabetes-associated autoantibodies in non-insulin-requiring adult-onset diabetes in a Chinese population.

In the European Action LADA study, 90 % of adult-onset diabetes patients had GADA, while IA-2A and ZnT8A only identified 10 % of the remaining cases \[[@CR3]\]. In the Italian NIRAD study, 96 % of adult-onset autoimmune diabetes patients had GADA, the remainder being identified by IA-2A and ZnT8A \[[@CR23]\]. In striking contrast, in this present Chinese study, only 67 % of autoimmune diabetes patients were GADA positive, though GADA was again the dominant autoantibody. About 33 % of adult-onset autoimmune diabetes Chinese patients were identified by autoantibodies other than GADA, including IA2A, ZnT8A, and IAA, a much higher frequency than that found in Europe. Though the numbers are small, those Chinese patients with diabetes-associated autoantibodies other than GADA did show a range of clinical differences compared with the type 2 diabetes mellitus cases, which is in line with European adult-onset autoimmune diabetes and consistent with these autoantibodies identifying a cohort of patients clinically different from type 2 diabetes mellitus \[[@CR21]\].

Limitations of our study include the possibility that we have detected false positives, despite the high specificity for our autoantibody assays and the repetition of the positive assays to both limit that error and increase the assay specificity. Despite the substantial numbers tested, the low positivity of IA-2A, ZnT8A, and IAA also limits the power of our analysis. Moreover, this present cohort probably excludes patients with the more aggressive form of adult-onset autoimmune diabetes, as we have excluded patients on insulin therapy in order to estimate IAA. In summary, while GADA detects about 90 % of autoimmune adult-onset diabetes patients in Europe, our results indicate that in China screening for diabetes-associated autoantibodies should include autoantibodies other than GADA.

Appendix {#Sec9}
========

LADA China investigators and Hospitals {#Sec10}
--------------------------------------

LinongJi, Peking University People's Hospital (Beijing); XiaohuiGuo, Peking University First Hospital (Beijing); Tianpei Hong, Peking University Third Hospital (Beijing); Jumin Lu, The General Hospital of the People's Liberation Army (Beijing); ZhangrongXu, The 306th Hospital of the People's Liberation Army (Beijing); Yingsheng Zhou, Beijing Hospital (Beijing); WeipingJia, Shanghai Jiao Tong University Affiliated 6th People's Hospital (Shanghai); NingGuang, Shanghai Jiao Tong University Affiliated Rui-Jin Hospital (Shanghai); RenmingHu, Hua Shan Hospital, Fudan University (Shanghai); XinGao, Zhongshan Hospital, Fudan University (Shanghai); Yanbing Li, The First Affiliated Hospital, Sun Yat-sen University (Guangzhou); Huazhang Yang, Guangdong General Hospital (Guangzhou); Shaoda Lin, the First Affiliated Hospital,Shantou University (Shantou); Shenren Chen, the Second Affiliated Hospital, Shantou University (Shantou); Lulu Chen, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (Wuhan); YanchengXu, Zhongnan Hospital of Wuhan University (Wuhan); Hong Li, First Affiliated Hospital of Medical School of Zhejiang University (Hangzhou); Wei Gu, Second Affiliated Hospital of Medical School of Zhejiang University (Hangzhou); Dawang Wang, The First Affiliated Hospital of Wenzhou Medical School (Wenzhou); Qifu Li, The First Affiliated Hospital, Chongqing Medical University (Chongqin); Gangyi Yang, The Second Affiliated Hospital, Chongqing Medical University (Chongqin); HaomingTian, West China Hospital, Sichuan University (Chengdu); Dalong Zhu, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School (Nanjing); Chao Liu, Jiangsu Province Hospital, the First Affiliated Hospital with Nanjing Medical University (Nanjing); QiuheJi, Xijing Hospital, Fourth Military Medical University (Xi'an); Zhongyan Shan, The First Hospital of China Medical University (Shenyang); Jianling Du, First Affiliated Hospital of Dalian Medical University (Dalian); Benli Su, Second Affiliated Hospital of Dalian Medical University (Dalian); Yan Liu, The Norman Bethune 1st hospital of Jilin University (Changchun); HuanqiGe, The Norman Bethune 2nd hospital of Jilin University (Changchun); Yadong Sun, People's Hospital of Jilin Province (Changchun); Qiang Li, The 2nd Affiliated Hospital of Harbin Medical University (Harbin); Jiajun Zhao, Shandong Provincial Hospital (Jinan); LingliOuyang, The First Affiliated Hospital of Guangxi Medical University (Nanning); YuexinBai, The First Affiliated Hospital of Zhengzhou University (Zhenzhou); YuanmingXue, The First People's Hospital of Yunnan Province (Kunming); Xulei Tang, The First Affiliated Hospital of Lanzhou University (Lanzhou); Lixin Shi, The Affiliated Hospital of Guiyang Medical College (Guiyang); Xiaoyang Lai, The Second Affiliated Hospital of Nanchang University (Nanchang); Jie Liu, Shanxi Provincial People's Hospital (Taiyuan); Liyong Yang, The First Affiliated Hospital of Fujian Medical University (Fuzhou); HuijuZhong, Xiangya Hospital of Central South University (Changsha); Zhiguang Zhou, The Second Xiangya Hospital of Central South University (Changsha); Jianying Liu, The First Affiliated Hospital of Nanchang University (Nanchang); Jing Yang, The First Hospital of Shanxi Medical University (Taiyuan); YongdePeng, Shanghai First People's Hospital (Shanghai).
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